Mouse DR3/TNFRSF25 Biotinylated Antibody Summary
Gln31-Phe199
Accession # AAK11256
Applications
Please Note: Optimal dilutions should be determined by each laboratory for each application. General Protocols are available in the Technical Information section on our website.
Reconstitution Calculator
Preparation and Storage
- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 6 months, -20 to -70 °C under sterile conditions after reconstitution.
Background: DR3/TNFRSF25
Death receptor 3 (DR3), also known as TNFRSF25, LARD, WSL-1, APO3, TRAMP, and TR3, is a 55 kDa TNF receptor superfamily protein that is predominantly expressed by lymphocytes. TNF receptor superfamily members have varying numbers of extracellular cysteine-rich domains (CRDs) with conserved cysteine spacing (1, 2). DR3 contains four CRDs and one cytoplasmic death domain (3, 4). Alternative splicing of mouse DR3 generates an isoform that lacks the fourth CRD and a secreted isoform that consisits of only the extracellular domain (ECD) (3). Human DR3 exists in at least eleven alternate splice forms (5). Within the ECD, mouse and human DR3 share 59% amino acid (aa) sequence identity. DR3 shares 20% - 28% aa sequence identity with the ECD of death domain receptors DR5, DR6, EDAR, Fas, NGF R, and TNF RI. Naïve B and T cells preferentially express truncated soluble isoforms of DR3, whereas stimulated lymphocytes preferentially express transmembrane DR3 (5). TL1A/TNFSF15, a high affinity DR3 ligand which also exists in membrane bound and soluble forms, is expressed by activated endothelial cells and T cells (6, 7). TL1A additionally binds to DcR3/TNFRSF6B, a soluble decoy receptor that interferes with DR3 activation (8). DR3 signaling triggers either apoptosis or NF kappa B-induced anti-apoptotic effects depending on the cellular setting (9). Apoptosis is partially impaired during negative selection of thymocytes in DR3-null mice (10). TL1A interactions with DR3 augment T cell proliferation and proinflammatory cytokine secretion (6, 7, 11, 12). DR3 is upregulated by inflammatory stimulation of CCR9+ T cells, a T cell subset important in mucosal immunity (11). T cell and macrophage DR3 expression is prominent in several inflammatory disorders such as Crohn’s disease, inflammatory bowel disease, and atherosclerosis (7, 11-15). DR3 activation on IFN-gamma treated THP-1 cells induces the production of TNF-alpha, CXCL8, CCL2, MMP-1, -9, and -13 (14, 15).
- Fas, S.C. et al. (2006) Curr. Dir. Autoimmun. 9:1.
- Aggarwal, B.B. (2003) Nat. Rev. Immunol. 3:745.
- Wang, E.C.Y. et al. (2001) Immunogenetics 53:59.
- Borysenko, C.W. et al. (2005) Biochem. Biophys. Res. Commun. 328:794.
- Screaton, G.R. et al. (1997) Proc. Natl. Acad. Sci. USA 94:4615.
- Migone, T.S. et al. (2002) Immunity 16:479.
- Prehn, J.L. et al. (2004) Clin. Immunol. 112:66.
- Yang, C-R. et al. (2004) Cancer Res. 64:1122.
- Wen, L. et al. (2003) J. Biol. Chem. 278:39251.
- Wang, E.C.Y. et al. (2001) Mol. Cell. Biol. 21:3451.
- Papadakis, K.A. et al. (2005) J. Immunol. 174:4985.
- Papadakis, K.A. et al. (2004) J. Immunol. 172:7002.
- Bamias, G. et al. (2003) J. Immunol. 171:4868.
- Kim, S-H. et al. (2001) Jpn. Circ. J. 65:136.
- Kang, Y-J. et al. (2005) Cytokine 29:229.
Product Datasheets
Citations for Mouse DR3/TNFRSF25 Biotinylated Antibody
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
4
Citations: Showing 1 - 4
Filter your results:
Filter by:
-
Cleavage of TL1A Differentially Regulates Its Effects on Innate and Adaptive Immune Cells
Authors: JR Ferdinand, AC Richard, F Meylan, A Al-Shamkha, RM Siegel
J. Immunol., 2018-01-15;0(0):.
Species: Mouse
Sample Types: Whole Cells
Applications: Flow Cytometry -
The TNF-family ligand TL1A and its receptor DR3 promote T cell-mediated allergic immunopathology by enhancing differentiation and pathogenicity of IL-9-producing T cells.
Authors: Richard A, Tan C, Hawley E, Gomez-Rodriguez J, Goswami R, Yang X, Cruz A, Penumetcha P, Hayes E, Pelletier M, Gabay O, Walsh M, Ferdinand J, Keane-Myers A, Choi Y, O'Shea J, Al-Shamkhani A, Kaplan M, Gery I, Siegel R, Meylan F
J Immunol, 2015-03-18;194(8):3567-82.
Species: Mouse
Sample Types: Whole Cells
Applications: IHC -
The death receptor 3/TL1A pathway is essential for efficient development of antiviral CD4(+) and CD8(+) T-cell immunity.
Authors: Twohig J, Marsden M, Cuff S, Ferdinand J, Gallimore A, Perks W, Al-Shamkhani A, Humphreys I, Wang E
FASEB J, 2012-05-16;26(8):3575-86.
Species: Mouse
Sample Types: Whole Cells
Applications: Flow Cytometry -
Expression of TNFRSF25 on conventional T cells and Tregs.
Authors: Taraban VY, Ferdinand JR, Al-Shamkhani A
J. Clin. Invest., 2011-02-01;121(2):463-4.
Species: Mouse
Sample Types: Whole Cells
Applications: Flow Cytometry
FAQs
No product specific FAQs exist for this product, however you may
View all Antibody FAQsReviews for Mouse DR3/TNFRSF25 Biotinylated Antibody
There are currently no reviews for this product. Be the first to review Mouse DR3/TNFRSF25 Biotinylated Antibody and earn rewards!
Have you used Mouse DR3/TNFRSF25 Biotinylated Antibody?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
